Browsing Tag
GLP-1
50 posts
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Are compounded weight-loss drugs the next opioid crisis? Inside the unregulated boom of off-label GLP-1s
Are GLP-1 weight-loss drugs like semaglutide fueling a new safety crisis? Explore the unregulated boom in compounded injections and FDA’s crackdown.
GLP-1 crackdown intensifies: What FDA’s new green list means for tirzepatide safety
The FDA’s new GLP-1 green list aims to block illegal semaglutide and tirzepatide imports. Find out how it could reshape the compounding pharmacy landscape.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
Is protein personalization the next frontier in sports nutrition and metabolic health?
Explore how personalized protein blends are transforming sports nutrition and metabolic health by 2027. Learn about biomarker-driven customization, market growth, and investor moves.
OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation
OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.